Abstract
Lenalidomide is a heterocyclic drug used for the treatment of Myelodysplastic syndrome. The current research focuses on the structural elucidation of new degradants that are formed unexpectedly upon storage of lenalidomide in methanol, followed by proposing their corresponding formation mechanism. The proposed structures of the degradants are relatively stable in which two tetrahedral intermediates are resulted from nucleophilic addition of methanol to the carbon of the carbonyl group of imide ring. Methanol molecules, as a solvent, may contribute in stabilizing the intermediate via hydrogen bond formation with it. These degradants were found abundant in lenalidomide/ methanol solution. Hence, the toxicological evaluation of them is crucial.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
